By the Atlanta Symphony Orchestra end of 2010 Alnylam expects to broaden

By the surmises atlanta symphony orchestra chorus end of symphony orchestra defines 2010, Alnylam expects to broaden itsleadership and significantly expand the scope of delivery solutions for RNAitherapeutics. This will be achieved by the continued scientific leadership ofAlnylam scientists and current academic and industry collaborators, but also asignificant external effort to form new delivery technology partnerships.Further, this effort will include the significant expansion of the range oftissues and cell types where the company aims to achieve efficient delivery ofRNAi therapeutics with both direct and systemic delivery approaches * Clinical Pipeline. By the end of 2010, Alnylam expects to have four or moreRNAi therapeutic programs in clinical development. These include direct andsystemic RNAi programs, Alnylam proprietary and 50-50 partnership programs, andsiRNA and microRNA therapeutics * New Business Collaborations.

Based on its scientific, clinical, andintellectual property leadership, the company also expects to form four or morenew major business collaborations by the end of 2010 Atlanta Symphony Orchestra . These are expected toinclude the completion of additional broad platform alliances similar to thecompany`s July 2007 partnership with Roche youth orchestra . Completion of these businesscollaborations is expected to provide the company significant resources andfunding to advance Alnylam`s proprietary and 50-50 partnership pipelineprograms.About RNA Interference (RNAi)RNAi (RNA interference) is a revolution in biology, representing a breakthroughin understanding how genes are turned on and off in cells, and a completely newapproach to drug discovery and development orchestra . Its discovery has been heralded as"a major scientific breakthrough that happens once every decade or so," andrepresents one of the most promising and rapidly advancing frontiers in biologyand drug discovery today which was awarded the 2006 Nobel Prize for Physiologyor Medicine youth symphony . RNAi is a natural process of gene silencing that occurs inorganisms ranging from plants to mammals.

By harnessing the natural biologicalprocess of RNAi occurring in our cells, the creation of a major new class ofmedicines, known as RNAi therapeutics, is on the horizon . RNAi therapeuticstarget the cause of diseases by potently silencing specific messenger RNAs(mRNAs), thereby preventing disease-causing proteins from being made philharmonic orchestra . RNAitherapeutics have the potential to treat disease and help patients in afundamentally new way pops orchestra . About Alnylam PharmaceuticalsAlnylam is a biopharmaceutical company developing novel therapeutics based onRNA interference, or RNAi . The company is applying its therapeutic expertise inRNAi to address significant medical needs, many of which cannot effectively beaddressed with small molecules or antibodies, the current major classes ofdrugs. Alnylam is leading the translation of RNAi as a new class of innovativemedicines with peer-reviewed research efforts published in the world`s topscientific journals including Nature, Nature Medicine, and Cell. The company isleveraging these capabilities to build a broad pipeline of RNAi therapeutics;its most advanced program is in Phase II human clinical trials for the treatmentof respiratory syncytial virus (RSV) infection and is partnered with Cubist andKyowa Hakko.